Soleno Therapeutics to Participate in Upcoming June Conferences
REDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in June:
Jefferies Global Healthcare Conference
Presentation Date: Wednesday, June 4, 2025 at 10:30 AM ET
Presentation Format: Corporate Presentation
Webcast:
Goldman Sachs 46th Healthcare Conference
Presentation Date: Tuesday, June 10, 2025 at 8:40 AM ET
Presentation Format: Corporate Presentation
Webcast:
A replay of both events will be available in the Investors section on the Company’s website at .
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The Company’s first commercial product, VYKAT™ XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children four years of age and older with Prader-Willi syndrome. For more information, please visit .
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
